Precision Medicine and Immuno-Oncology China Summit 2017



攻克癌症成为各国精准医疗计划的中心。癌症的发病率增加以及医疗开支不上升推动市场的增长。根据美国市场研究公司markets and markets发布报告称,全球癌症免疫治疗市场的规模将从2016年的619亿美元,增长到2021年的1193.9亿美元,复合年增长率达14.0%。作为癌症免疫疗法中的主力军,PD-L1/PD-1抗体已经展现了良好的市场前景。另外,细胞治疗也备受关注。数据显示,截至到2016年6月,全球正在进行的CAR-T临床试验有173项,中国开展的CAR-T临床试验数量位居全球第二,共计30项,涉及24个靶点,仅次于美国。专家认为,随着基因诊断、免疫技术的不断进步,“基于细胞免疫治疗的联合疗法”可能彻底改变癌症治疗,是具有重大投资价值的人类突破性技术。


有关更多详细信息,请登录网址www.pmio-china.com或联系会务组8621-3112-3968,或发送邮件至[email protected]


Precision Medicine and Immuno-Oncology China Summit 2017

Curing cancers have come become the core part of PMI for different countries due to the rising incidence of cancer and associated medical expenditure. Based on authoritative report, the global market size for cancer immunotherapy will grow to roughly USD 100 billion in 2021 from USD 620 billion in 2016 with 14% CAGR. PD-L1/PD-1 antibody has demonstrated good market prospect. Besides, cellular therapy has attracted global attention. Based on statistics, there’re 173 ongoing CAR-T clinical trials in the world and China ranks 2nd next to US with 30 clinical trials and 24 targets. Experts think with advancements in gene diagnostics and immunotherapy, cell based combination therapy could be human ground breaking technology to completely change the way of curing cancers.

Under this background and co-organized by Chinese Biopharmaceutical Association (CBA) and SAPA-GP, Precision Medicine and Immuno-oncology China 2017 will be convened in April in Shanghai. With the background of precision medicine, the theme will be centered on recent advancement and application of precision medicine, immunotherapy, biologics development and molecular diagnostics. The show is intended to promote the translation of precision medicine from bench to beside and from application of genetic testing to personalized medicine. Meantime, we are building a premier networking platform for industry companies and capitals to work together in China’s precision medicine industry. The show will attract 300+ delegates from regulatory body, industry association, pharma, biotech companies, CROs, hospitals, research institutes, biobanks, solutions providers to explore best clinical practice of precision therapy, stem cell and combination therapy, exchange recent advancement of precision medicine R&D in big pharma, showcase frontier technology and applications, and explore collaboration between industry and academia. We cordially invite you to attend this international summit and discuss China’s promising future of precision medicine.

For more information, please visit, or call the organizing committee at 8621-3112-3968, or send your enquiries to [email protected].